Evidence map›Paper›PMID 26195743›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2015

Multitarget, quantitative nanoplasmonic electrical field-enhanced resonating device (NE2RD) for diagnostics.

Fatih Inci, Chiara Filippini, Murat Baday, Mehmet Ozgun Ozen, Semih Calamak, Naside Gozde Durmus, ShuQi Wang, Emily Hanhauser, Kristen S Hobbs, Franceline Juillard and 21 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. A Novel On-Chip Method for Differential Extraction of Sperm in Forensic Cases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2018
    Article
  9. Review
  10. Review
  11. Nanoswitch-linked immunosorbent assay (NLISA) for fast, sensitive, and specific protein detection.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Fatih InciDemirci Bio-Acoustic-Microelectromechanical Systems in Medicine (BAMM) Laboratory, Canary Center at Stanford for Cancer Early Detection, Radiology Department, Stanford University School of Medicine, Palo Alto, CA 94304;
Chiara FilippiniDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115;
Murat BadayDemirci Bio-Acoustic-Microelectromechanical Systems in Medicine (BAMM) Laboratory, Canary Center at Stanford for Cancer Early Detection, Radiology Department, Stanford University School of Medicine, Palo Alto, CA 94304; jeanne.thompson@stanford.edu utkan@stanford.edu.
Mehmet Ozgun OzenDemirci Bio-Acoustic-Microelectromechanical Systems in Medicine (BAMM) Laboratory, Canary Center at Stanford for Cancer Early Detection, Radiology Department, Stanford University School of Medicine, Palo Alto, CA 94304;
Semih CalamakDemirci Bio-Acoustic-Microelectromechanical Systems in Medicine (BAMM) Laboratory, Canary Center at Stanford for Cancer Early Detection, Radiology Department, Stanford University School of Medicine, Palo Alto, CA 94304;
Naside Gozde DurmusDepartment of Biochemistry, Stanford University School of Medicine, Stanford, CA 94304; Stanford Genome Technology Center, Stanford University, Palo Alto, CA 94304;
ShuQi WangDemirci Bio-Acoustic-Microelectromechanical Systems in Medicine (BAMM) Laboratory, Canary Center at Stanford for Cancer Early Detection, Radiology Department, Stanford University School of Medicine, Palo Alto, CA 94304; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China; Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, Zhejiang, 310003, China; Institute for Translational Medicine, Zhejiang University, Hangzhou, Zhejiang, 310029, China;
Emily HanhauserDivision of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115;
Kristen S HobbsDivision of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115;
Franceline JuillardDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115;
Ping Ping KuangDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115;
Michael L VetterDepartment of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115;
Margot CarocciDepartment of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115;
Hidemi S YamamotoLaboratory of Genital Tract Biology, Department of Obstetrics, Gynecology, Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115;
Yuko TakagiDepartment of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115;
Umit Hakan YildizDemirci Bio-Acoustic-Microelectromechanical Systems in Medicine (BAMM) Laboratory, Canary Center at Stanford for Cancer Early Detection, Radiology Department, Stanford University School of Medicine, Palo Alto, CA 94304;
Demir AkinMolecular Imaging Program at Stanford, Center for Cancer Nanotechnology Excellence, Stanford University, Palo Alto, CA 94305; Department of Radiology, Stanford University School of Medicine, Stanford, CA 94304;
Duane R WesemannDepartment of Medicine, Harvard Medical School, Boston, MA 02115; Department of Radiology, Stanford University School of Medicine, Stanford, CA 94304;
Amit SinghalSingapore Immunology Network, Agency for Science Technology and Research (A*STAR), Singapore 138648;
Priscilla L YangDepartment of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115;
Max L NibertDepartment of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115;
Raina N FichorovaLaboratory of Genital Tract Biology, Department of Obstetrics, Gynecology, Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115;
Daryl T-Y LauDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115;
Timothy J HenrichDivision of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115;
Kenneth M KayeDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115;
Steven C SchachterDepartment of Neurology, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115;
Daniel R KuritzkesDivision of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115;
Lars M SteinmetzStanford Genome Technology Center, Stanford University, Palo Alto, CA 94304;
Sanjiv S GambhirMolecular Imaging Program at Stanford, Center for Cancer Nanotechnology Excellence, Stanford University, Palo Alto, CA 94305; Department of Radiology, Stanford University School of Medicine, Stanford, CA 94304; Department of Bioengineering, Stanford University, Stanford, CA 94305; Department of Materials Science and Engineering, Stanford University, Stanford, CA 94305; Bio-X Program, Stanford University, Stanford, CA, 94305;
Ronald W DavisDepartment of Biochemistry, Stanford University School of Medicine, Stanford, CA 94304; Stanford Genome Technology Center, Stanford University, Palo Alto, CA 94304; jeanne.thompson@stanford.edu utkan@stanford.edu.
Utkan DemirciDemirci Bio-Acoustic-Microelectromechanical Systems in Medicine (BAMM) Laboratory, Canary Center at Stanford for Cancer Early Detection, Radiology Department, Stanford University School of Medicine, Palo Alto, CA 94304; Department of Electrical Engineering (By courtesy), Stanford University, Stanford, CA 94305 jeanne.thompson@stanford.edu utkan@stanford.edu.

Funding

WHOLE YEAST GENOME TRANSCRIPTIONAL AND FUNCTIONAL GENE MAPS--A FEASIBILITY STUDYP01HG000205 · NHGRI · STANFORD UNIVERSITY · PI DAVIS, RONALD WAYNE, HOWE, ROGER THOMAS · 1990 to 2016
$120.9M
Treatments for Nipah Virus InfectionU54AI057159 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WHELAN, SEAN PJ · 2003 to 2013
$113.7M
Rapid Fluorescence-Based Determination of Antibiotic SusceptibilityU54EB015408 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI PARRISH, JOHN A, SCHACHTER, STEVEN · 2012 to 2022
$49.2M
INFECTIOUS DISEASE AND BASIC MICROBIOLOGICAL MECHANISMST32AI007061 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Marcia B Goldberg · 1985 to 2026
$12.1M
Nano Characterization and Nano Fabrication CoreU54CA199075 · NCI · STANFORD UNIVERSITY · PI GAMBHIR, SANJIV S · 2015 to 2019
$9.6M
GENETIC AND BIOCHEMICAL STUDIES OF THE KSHV LANA GENER01CA082036 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI KAYE, KENNETH M · 1999 to 2019
$7.6M
Decrypting IgE B Cell ImmunobiologyR01AI121394 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI WESEMANN, DUANE R. · 2016 to 2020
$3.1M
Molecular T. vaginalis-host interactions in relevance to inflammatory sequelaeR01AI079085 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI FICHOROVA, RAINA N. · 2009 to 2012
$3.0M
Point-of-Care Rapid Blood Testing Using Microfluidic DevicesR01AI081534 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI DEMIRCI, UTKAN · 2009 to 2013
$2.1M
Validation of Src kinases as Anti-Dengue Viral TargetsR01AI076442 · NIAID · HARVARD MEDICAL SCHOOL · PI YANG, PRISCILLA LI-NING · 2008 to 2012
$2.1M
Novel disposable microchips for HIV-1 viral loadR01AI093282 · NIAID · STANFORD UNIVERSITY · PI DEMIRCI, UTKAN · 2012 to 2015
$1.7M
Chemical Tools for the Study of Dengue Virus EntryR01AI095499 · NIAID · HARVARD MEDICAL SCHOOL · PI GRAY, NATHANAEL SCHIANDER, YANG, PRISCILLA LI-NING · 2014 to 2016
$1.3M
NCI NIH HHS R01 CA082036NCI NIH HHS R01CA082036NHGRI NIH HHS P01 HG000205NIAID NIH HHS 01AI093282NIAID NIH HHS 5T32AI007061NIAID NIH HHS R01 AI076442NIAID NIH HHS R01AI076442NIAID NIH HHS R01 AI079085NIAID NIH HHS R01AI079085NIAID NIH HHS R01 AI081534NIAID NIH HHS R01AI081534NIAID NIH HHS R01 AI093282NIAID NIH HHS R01 AI095499NIAID NIH HHS R01 AI121394NIAID NIH HHS R21 AI087107NIAID NIH HHS R21AI087107NIAID NIH HHS R56 AI091889NIAID NIH HHS R56AI091889NIAID NIH HHS T32 AI007061NIAID NIH HHS U54 AI057159NIAID NIH HHS U54AI057159NIBIB NIH HHS U54 EB015408NIBIB NIH HHS U54EB15408
6 · The paper itself

Abstract

Recent advances in biosensing technologies present great potential for medical diagnostics, thus improving clinical decisions. However, creating a label-free general sensing platform capable of detecting multiple biotargets in various clinical specimens over a wide dynamic range, without lengthy sample-processing steps, remains a considerable challenge. In practice, these barriers prevent broad applications in clinics and at patients' homes. Here, we demonstrate the nanoplasmonic electrical field-enhanced resonating device (NE(2)RD), which addresses all these impediments on a single platform. The NE(2)RD employs an immunodetection assay to capture biotargets, and precisely measures spectral color changes by their wavelength and extinction intensity shifts in nanoparticles without prior sample labeling or preprocessing. We present through multiple examples, a label-free, quantitative, portable, multitarget platform by rapidly detecting various protein biomarkers, drugs, protein allergens, bacteria, eukaryotic cells, and distinct viruses. The linear dynamic range of NE(2)RD is five orders of magnitude broader than ELISA, with a sensitivity down to 400 fg/mL This range and sensitivity are achieved by self-assembling gold nanoparticles to generate hot spots on a 3D-oriented substrate for ultrasensitive measurements. We demonstrate that this precise platform handles multiple clinical samples such as whole blood, serum, and saliva without sample preprocessing under diverse conditions of temperature, pH, and ionic strength. The NE(2)RD's broad dynamic range, detection limit, and portability integrated with a disposable fluidic chip have broad applications, potentially enabling the transition toward precision medicine at the point-of-care or primary care settings and at patients' homes.

Indexed as

ElectricityBiosensing TechniquesCell Line, TumorCoinfectionDiagnostic Techniques and ProceduresEnvironmentEnzyme-Linked Immunosorbent AssayEquipment DesignHumansHydrogen-Ion ConcentrationLimit of DetectionMicrofluidicsNanostructuresOsmolar ConcentrationReproducibility of ResultsTemperaturebiodetectionlabel-freemultiple biotargetsnanoparticlepoint-of-need

Identifiers

PMID26195743
PMCPMC4538635

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.